Children with Down's syndrome (DS) have an increased risk of developing acute lymphoblastic leukemia (ALL) and have a low frequency of established genetic aberrations. We aimed to determine which genetic abnormalities are involved in DS ALL. We studied the frequency and prognostic value of deletions in B-cell development genes and aberrations of janus kinase 2 (JAK2) and cytokine receptor-like factor 2 (CRLF2) using array-comparative genomic hybridization, and multiplex ligation-dependent probe amplification in a population-based cohort of 34 Dutch Childhood Oncology Group DS ALL samples. A population-based cohort of 88 DS samples from the UK trials was used to validate survival estimates for IKZF1 and CRLF2 abnormalities. In total, 50% of DS ALL patients had X1 deletion in the B-cell development genes: PAX5 (12%), VPREB1 (18%) and IKZF1 (35%). JAK2 was mutated in 15% of patients, genomic CRLF2 rearrangements in 62%. Outcome was significantly worse in patients with IKZF1 deletions (6-year eventfree survival (EFS) 45 ± 16% vs 95 ± 4%; P ¼ 0.002), which was confirmed in the validation cohort (6-year EFS 21 ± 12% vs 58 ± 11%; P ¼ 0.002). This IKZF1 deletion was a strong independent predictor for outcome (hazard ratio EFS 3.05; P ¼ 0.001). Neither CRLF2 nor JAK2 were predictors for worse prognosis. If confirmed in prospective series, IKZF1 deletions may be used for risk-group stratification in DS ALL.
INTRODUCTION
Children with Down's syndrome (DS) have an increased risk of developing acute myeloid leukemia and acute lymphoblastic leukemia (ALL). 1 Although acute myeloid leukemia in children with DS is characterized by unique acquired mutations in the transcription factor GATA1 (globin transcription factor 1), [2] [3] [4] there is no evidence as yet for such a unique genetic event in DS ALL.
The established cytogenetic abnormalities, such as high hyperdiploidy (51-65 chromosomes), ETV6-RUNX1, BCR-ABL1, MLL-rearrangements and TCF3-PBX1, occur in about two-third of non-DS B-cell precursor ALL patients. However, these abnormalities are found only in approximately 20% of DS children with ALL. 5, 6 Recently, genomic abnormalities of cytokine receptor-like factor 2 (CRLF2) have been described in approximately 60% of DS ALL patients. 7 These rearrangements include (a) translocations of CRLF2 with the immunoglobulin heavy chain locus (IGH@) at chromosome 14q32 and (b) interstitial deletions in the pseudoautosomal region 1 resulting in P2RY8-CRLF2 fusion. [7] [8] [9] Functionally, both aberrations result in overexpression of CRLF2 and activation of the JAK-STAT pathway. [7] [8] [9] Activating mutations in amino-acid R683 of janus kinase 2 (JAK2) occur in around 20% of DS ALL cases, which were initially thought to be unique to DS ALL. 6, [10] [11] [12] Mutations of JAK2 and rearrangements of CRLF2 are found in o10% and up to 15% of high-risk non-DS ALL patients, respectively. 8, [12] [13] [14] [15] [16] Deletions in B-cell development and differentiation genes, including IKZF1, TCF3, EBF1, PAX5 and VPREB1, have recently been described in DS and non-DS ALL. [17] [18] [19] [20] The prognostic significance of abnormalities of these genes in DS ALL is currently unknown. Therefore, we analyzed a population-based cohort of DS ALL samples for deletions in these genes using genomic profiling and related these to clinical outcome. The survival parameters were validated using another population-based cohort of DS ALL patients from UK trials for abnormalities involving IKZF1 and CRLF2.
MATERIALS AND METHODS

Patients and patient samples
We identified all DS ALL patients (n ¼ 58) enrolled in three consecutive Dutch Childhood Oncology Group (DCOG) ALL treatment protocols (DCOG ALL8, ALL9 and ALL10). Details of DCOG ALL8 and ALL9 have been reported elsewhere, and ALL10 is currently ongoing (Supplementary Figure 1) . 21, 22 In addition, we identified all DS ALL patients (n ¼ 114) enrolled in the UK National Cancer Research Institute Childhood Cancer and Leukaemia Group treatments protocols ALL97, ALL97/99 and ALL2003, which were used as a validation cohort. 23, 24 Both, DCOG and the UK treatment protocols were approved by the Institutional Review Board of the participating centers according to local law and guidelines, and informed consent was obtained from all the patients, their parents or guardians. Data on clinical characteristics, biological features and outcome were extracted from national databases. Vials with frozen cells were available from 34/58 DCOG patients. After thawing, contaminating non-leukemic cells were eliminated as previously described. 25 Blast percentages were assessed morphologically on MayGrü nwald-Giemsa-stained cytospin slides. All patient samples contained X80% leukemic blasts (median 95.5%, range 83-99%). Genomic DNA and total cellular RNA were extracted from leukemic cells using Trizol reagent (Gibco BRL, Life Technologies, Breda, the Netherlands), as previously described. 25 DNA quality was tested using gel electrophoresis and its quality and quantity were measured on the Nanodrop 1000 spectrophotometer (Isogen, De Meern, the Netherlands). Analyses for the UK patients (n ¼ 88) were performed on pre-treatment samples using the standard methodologies and were reported using established nomenclature and definitions. 26, 27 Cytogenetics and fluorescence in situ hybridization (FISH) Diagnostic samples were routinely analyzed using the standard cytogenetic procedures by the reference cytogenetic laboratories in the University Hospitals participating in the DCOG and UK trials. Ploidy status was determined from the karyotypes; if these data were missing, arraycomparative genomic hybridization (CGH) results were used. Hypodiploidy was defined as o47 chromosomes, diploidy was defined as 47 chromosomes, low hyperdiploidy as X48 or p50 chromosomes and high hyperdiploidy asX51 chromosomes. All DCOG and UK samples were further analyzed for the presence of the ETV6-RUNX1 fusion using FISH with the dual-color translocation probe set: LSI ETV6 (TEL)/RUNX1(AML1)ES (Vysis, Downers Grove, IL, USA).
Genomic CRLF2 aberrations in the DCOG and UK cohorts and IKZF1 deletions in the UK cohort were detected using FISH as previously described. 8, 16 Briefly, we used a break-apart FISH probe to identify CRLF2 involvement. A break-apart probe to P2RY8 was designed to map the centromeric breakpoint of the deletion in patients with loss of the centromeric signal indicating deletion within the pseudoautosomal region centromeric of CRLF2. Combined results from these two break-apart probes indicated the presence of the P2RY8-CRLF2 fusion. The involvement of IGH@ was determined by interphase FISH using the LSI IGH Dual-Color Break-Apart Rearrangement Probe (Abbott Diagnostics, Hoofddorp, The Netherlands). Results were recorded using a Zeiss Axioscop fluorescence microscope (Zeiss, Sliedrecht, The Netherlands) fitted with a 100_/1.30 oil objective, CCD camera and digital imaging software: ISIS software version 5.1.9 (Metasystems, Altlussheim, Germany) and Cytovision Version 4.5 (Leica Microsystems, Milton Keynes, UK).
Array-comparative genomic hybridization
To identify copy number changes, particularly in the B-cell development and differentiation genes: PAX5, VPREB1, TCF3, EBF1 and IKZF1, we performed 105-K oligonucleotide array-CGH on genomic DNA on the DCOG cohort as previously described. 17, 28 Genomic losses and gains were identified as a minimum of three consecutive probes deviating beyond the threshold of À 0.8 for single copy loss and À 1.8 for bi-allelic loss (log ratio). Deletions were defined as a loss X0.5 million bases, whereas focal deletions were defined as losses o0.5 million bases. 17 To further specify deletions of IKZF1 in the DCOG cohort, genomic DNA was PCR amplified to detect isoform 6 of the IKZF1 gene with primers previously described. 19 
Mutation analysis
To analyze mutations in the coding exons of IKZF1 (exon 2-8) and in the JAK2 R683, PCR amplified DNA was purified and bidirectionally sequenced as previously described. 8, 29, 30 Multiplex ligation-dependent probe amplification (MLPA) MLPA was used in both DCOG and UK cases for detection and validation of aberrations in B-cell development and differentiation genes found by array-CGH and to further define IKZF1 deletions into different splice variants. MLPA analysis was performed using the SALSA MLPA kit P335-A3 ALL-IKZF1, which contains probes for selected B-cell development and differentiation genes, and the SALSA MLPA kit P202-A1 IKZF1, which contains an increased density of probes for IKZF1 (MRC-Holland, Amsterdam, The Netherlands). The full list and location of the MLPA probes can be downloaded from the MRC-Holland website (http://www. mrc-holland.com). The data were normalized by dividing the peak area of each probe by the mean peak area of the control probes. Peak heights o0.7 (0.75 for MRC UKALL samples) and 41.3 times the control peak height were considered abnormal, with those o0.7 representing deletions and those 41.3 representing duplications. 31, 32 Gene-expression profiling and quantitative real-time PCR (RT-PCR) Biotinylated cRNA of DCOG subjects was synthesized, hybridized and processed to Affymetrix U133 plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA) as previously described. 17, 31 Data were acquired using Expresso (BioConductor package Affymetrix) and probe-set intensities were normalized using the variance-stabilization normalization BioConductor package in the statistical data analysis environment R, version 2.7.0. Variance-stabilization normalization RMA normalized data were used to test for statistical differences in the expression of CRLF2 (probe set 208303_s_at). We performed quantitative RT-PCR 33 with primers as previously described and used SYBRgreen (Finnzymes, Vantaa, Finland) for expression analysis. 7 The average cycle threshold (Ct) value was used to calculate mRNA expression levels of CRLF2 relative to the expression level of the reference gene 'ribosomal protein S20' (RPS20) by use of the comparative cycle time (_Ct) method. 34 
Statistics
For statistical comparisons, the Statistical Package for the Social Sciences Analysis system (v.15.0, SPSS Inc., Chicago, IL, USA) was used. To compare categorical variables, we used w 2 analyses, for continuous variables, the Mann-Whitney U-test and Spearman's Rho (r) was used to calculate correlation coefficients. P-values p0.05 were considered statistically significant (two-tailed testing).
To evaluate the outcomes, statistical analyses were conducted using SAS software (SAS-PC, Version 9.1, Cary, NC, USA). Complete remission was defined as o5% blast in the bone marrow, with regeneration of tri-lineage hematopoiesis plus absence of leukemic cells in the cerebrospinal fluid or elsewhere. Event-free survival (EFS) was calculated from the date of diagnosis to the date of last follow-up or to the first event, including relapse, death in complete remission and failure to achieve complete remission (considered as event on day 0). Early death was defined as any death within the first 6 weeks of treatment and was considered as an event on day 0. Overall survival (OS) was measured from the date of diagnosis to the date of last follow-up or to the date of death from any cause. The Kaplan-Meier method was used to estimate survival rates, and survival estimates were compared using the log-rank test. The cumulative incidence of relapse (CIR), with other events and death in complete remission as competing events, was constructed by the method of Kalbfleisch and Prentice and compared using the Gray test.
For multivariate analysis, a stepwise Cox proportional-hazard regression model was used. Data from both the DCOG and UK validation cohorts were merged for this purpose. Continuous variables known to be of prognostic value in ALL were categorized according to the National Cancer Institute risk criteria, 35 and with the cut-offs previously described in DS ALL and BFM-95.
36,37
RESULTS
Patient samples and characteristics
A total of 34/58 (59%) DCOG and 88/114 (77%) UK DS ALL patients were enrolled in this study. All the 122 patients were classified as B-cell precursor ALL and treated with curative intent. The clinical and presenting characteristics of the tested cohort and the remaining DS ALL samples (residual cohort), for both DCOG and UK, were compared to test for selection bias and no differences were detected (Supplementary Tables 1 and 2 ). Furthermore, we tested for differences between the DCOG and UK sample cohorts (Table 1) . Patients from the UK trials had a lower 6-year survival estimate, which was due to a higher rate of death and relapse in early treatment protocols. 38 In addition, white blood cell count was slightly higher in the UK patients then in the DCOG patients (18.8 vs 8.8 Â 10 9 /l; P ¼ 0.07).
Cytogenetics and FISH Cytogenetic data were available for 31/34 DCOG patients (3 were based on array-CGH) and 88 UK patients (Supplementary  Tables 3a and b , respectively). A normal karyotype was found in 14 (45%) DCOG and 34 UK patients based on the full analysis of least 10 cells (there was failure to achieve a successful karyotype in 6 UK patients); one DCOG patient had a BCR-ABL1 fusion, whereas one DCOG and two UK patients had t(8;14)(q11;q32). 5 The gain of an X chromosome was observed in 6 DCOG and 18 UK patients, which were identified as additional-derived X chromosomes. 5 The remaining patients (n ¼ 15, 48%) had random cytogenetic aberrations. The ETV6-RUNX1 fusion was found in 2 (6%) DCOG patients and 15/85 (18%) UK patients.
Ploidy status of DCOG patients was determined from karyotypes (n ¼ 31) and from array-CGH (n ¼ 3). Four (12%) patients had a high hyperdiploid karyotype (X52 chromosomes), including trisomy 10 (n ¼ 4), trisomy 4 or 18 (n ¼ 3) and tetrasomy 21 (including the constitutional gain) (n ¼ 2). A similar proportion of the UK patients (4/73, 5.5%) had a high hyperdiploid karyotype and included trisomy of 4 (n ¼ 5), 10 (n ¼ 4) and 18 (n ¼ 4) and tetrasomy 21 (n ¼ 5).
In 21/33 (64%) DCOG DS ALL patients, CRLF2 was aberrant, including IGH@-CRLF2 (n ¼ 5) and P2RY8-CRLF2 (n ¼ 16). One patient could not be evaluated due to the poor quality of the material. In the UK cohort, 43/84 (52%) DS ALL patients had lesions of CRLF2, with 6/84 (7%) IGH@-CRLF2 translocations and 37/84 (44%) P2RY8-CRLF2 fusions. Four patients were not tested for IGH@-CRLF2, but were negative for P2RY8-CRLF2.
Array-comparative genomic hybridization In total, 17/34 (50%) DCOG cases had X1 deletion of B-cell development and differentiation genes (Supplementary Table 3 ).
Affected genes included the transcription factors: IKZF1 (n ¼ 12, 35%), VPREB1 (n ¼ 6, 18%) and PAX5 (n ¼ 4, 12%). Eight patients had focal deletions within IKZF1, two patients had a focal deletion of IKZF1 including the 3 0 flanking region and two patients had a deletion of the entire gene, as the whole chromosome 7p arm was deleted (Figure 1 ). In six of the patients with focal deletions within IKZF1, exon 3 through 6 was deleted, which was validated using PCR. This deletion results in the expression of isoform 6, a dominant-negative form of IKZF1. 18 No deletions were found in EBF1 or TCF3. Deletions in the PAX5 gene were always part of larger deleted regions, whereas deletions of the other genes were mainly focal. Aberrations of IKZF1 were not mutually exclusive: that is, in four cases, an IKZF1 deletion was found in combination with a PAX5 or VPREB1 deletion. Overlap between IKZF1, CRLF2 and JAK2 aberrations are depicted in Figure 2 .
Mutation analysis
No additional mutations were found after sequencing the coding exons (2-8) of IKZF1 in DCOG DS ALL patients. Synonymous polymorphisms were found at P334 in six patients (17.6%) and at N392 in two (5.9%) patients. JAK2 R683-activating mutations were found in 5/34 (15%) of the DCOG DS ALL patients as previously reported. 30 The incidence of JAK2 R683 mutations was higher in the UK cohort (8/20, 40%) as previously reported. 16 
MLPA
The SALSA MLPA P202-A1 IKZF1 kit, with the majority of probes targeting IKZF1, confirmed that 12/34 (35%) of the DCOG DS ALL patients had deletions of IKZF1 that were identical to those detected by array-CGH.
Using the SALSA MLPA P335-A3 ALL-IKZF1 kit, the same results were achieved for IKZF1 deletions as with the P202 MLPA kit. In addition, in four patients (12%), all probes for PAX5 were deleted, whereas no focal deletions of PAX5 were seen. No aberrations of EBF1 (0/34) were detected. In the UK cohort, IKZF1 was found to be aberrant in 23/85 (27%) patients, of which 5 (29%) resulted in IKZF1 isoform 6, 5 (29%) had whole-gene deletions and 7 (41%) had different deletion profiles. Interestingly, patients with IKZF1 deletions are significantly older then patients with wild-type IKZF1 (8.2 vs 4.3; P ¼ 0.03) ( Table 2) .
Gene-expression profiling and RT-PCR Of the 23 DCOG DS ALL patients, RNA was available for geneexpression profiling and RT-PCR. The median variance-stabilization normalized expression value of patients with P2RY8-CRLF2 (n ¼ 11; median 9.4) was significantly higher than in patients with wildtype CRLF2 (n ¼ 8; median 7.8; P ¼ 0.001), and was also higher as compared with patients with IGH@-CRLF2 (n ¼ 4; median 8.4; P ¼ 0.001) (Figure 3a) , which was confirmed using RT-PCR (correlation coefficient of r ¼ 0.7, P ¼ 0.0002) (Figure 3b) . The median relative mRNA expression of CRLF2 in patients with P2RY8-CRLF2 was 6.5-fold higher (median 6.5) than in patients with IGH@-CRLF2 (median: 0.001) and wild-type CRLF2 (median: 0.001); Po0.001.
Univariate survival analysis
The median follow up time for survivors in the DCOG sample cohort was 5.7 years (range 1.2-15.4 years), the median follow up time for the UK survivors was 4.6 years (range 0.4-12.0 years). The 6-year EFS was 76±8.2%, the 6-year OS 85±6.2% and the CIR was 18±8% in DCOG DS ALL patients. The UK DS ALL patients had a 6-year EFS of 58 ± 6%, a 6-year OS of 63 ± 6.1% and a CIR of 16 ± 5%.
DCOG DS ALL patients with a white blood cell count X20 Â 10 9 /l at diagnosis (n ¼ 11) had a significantly worse outcome than patients with lower white blood cell count (n ¼ 23) (6-year EFS 38 ± 16.1% vs 96 ± 4.3%; Po0.001 and 6-year OS 60±15.5% vs 96±4.3%; P ¼ 0.005), and this was confirmed in the UK cohort (6-year EFS 43±8.7% vs 70±7.4%; P ¼ 0.01 and 6-year OS 50 ± 8.6% vs 70 ± 8.3%; P ¼ 0.03). There was no significant difference in outcome for patients below or above 6 years of age at diagnosis in both DCOG and UK patients.
Patients with an IKZF1 deletion (n ¼ 12) had a significantly worse outcome than patients without an IKZF1 deletion. In fact, with the exception of a single patient, all seven events occurred in patients with an IKZF1 deletion. The 6-year EFS was 45±16% for IKZF1-deleted vs 95 ± 4% for IKZF1 wild-type patients; P ¼ 0.002, OS 66 ± 14% vs 95 ± 4%; P ¼ 0.02 and CIR 37 ± 16% vs 5 ± 5%; P (gray) ¼ 0.044. The poor outcome for IKZF1-deleted patients was confirmed in the UK cohort (EFS 21±12% vs 58±11%; P ¼ 0.002, OS 15 ± 12 vs 71 ± 9%, P ¼ 0.02; and CIR 37 ± 15% vs 18 ± 10%, P (gray) ¼ 0.06) (Figure 4 ). Also when we combined the DCOG and the UK cohort (EFS 31±10% vs 75±7%; Po0.001, OS 40±10% vs 82±6%; P ¼ 0.0003 and CIR 37±11% vs 11±6%; P (gray) ¼ 0.007) (Supplementary Figure 2) , the poor outcome of IKZF1-deleted cases was evident.
There was no statistically significant difference in clinical outcome between patients with or without genomic CRLF2 aberrations, neither in the DCOG cohort (EFS 75 ± 10% vs 95 ± 14% in CRLF2 wild-type patients; P ¼ 0.6, OS 81 ± 9% vs 92±8%; P ¼ 0.42 and CIR 15±8% vs 21±15%; P (gray) ¼ 0.9, Supplementary Figure 3 ) nor in the UK cohort (EFS 50 ± 9% vs 70 ± 8%; P ¼ 0.10, OS 58 ± 9% vs 71 ± 9%; P ¼ 0.12 and CIR 22 ± 8 vs 11±5%; P (gray) ¼ 0.32, Supplementary Figure 4) .
The OS for DCOG patients with a PAX5 deletion was significantly lower compared with those with wild-type PAX5 due to the IKZF1 and CRLF2 aberrations in Down's syndrome ALL TD Buitenkamp et al poor salvage rate at relapse (OS 50 ± 25% vs 90 ± 6%; P ¼ 0.03).
No statistically significant differences in outcome were found in DCOG patients with and without a deletion of VPREB1 (OS 67±9% vs 89 ± 6%; P ¼ 0.12, CIR 17 ± 17% vs 18 ± 9%; P (gray) ¼ 0.85), nor for JAK2 R683 (data not shown).
Multivariate survival analysis A stepwise multivariate Cox regression model was performed on the total data set (DCOG and UK) for enough statistical power and included white blood cell count at diagnosis (X20 Â 10 9 /l), sample cohort, and mutational status of IKZF1 and genomic CRLF2 aberrations were variables included in the multivariate model.
Deletions of IKZF1 appeared to be the strongest independent risk factor for EFS, OS and relapse-free survival with a hazard ratio (HR) for EFS of 3.05 (95% confidence interval (CI) 1.55-6.02; P ¼ 0.001), for OS of 2.82 (95% CI 1.40-5.70; P ¼ 0.003) and for relapse-free survival of 7.83 (95% CI 2.39-25.63; P ¼ 0.001). The cohort (UK vs DCOG) was also an independent risk factor for EFS and OS but not for relapse-free survival (EFS: HR 2.37, 95% CI 1.01-5.54; P ¼ 0.046 and OS: HR 3.26, 95% CI 1.23-8.65; P ¼ 0.02 (Table 3) . Genomic CRLF2 aberrations were not a predictor for prognosis.
DISCUSSION
When assessing overall outcome, children with DS ALL have fared less well than their non-DS counterparts in most clinical trials. [39] [40] [41] [42] [43] There is a need to understand as to which genetic abnormalities contribute to the development of ALL in DS children and which abnormalities predict for poor outcome. This study has focused on the frequency and prognostic value of aberrations involving B-cell development and differentiation genes in DS ALL patients, especially IKZF1 deletions, based on recent findings in non-DS high-risk ALL, and the recent detection of patients with a BCR-ABL1-like gene-expression signature by Den Boer et al. 17 from our department, with a high-risk of recurrent disease. 18 Aberrations in genes encoding for B-cell development and differentiation are common in non-DS B-cell precursor ALL. The frequency varies between 67% in high-risk non-DS ALL and 82% in non-DS patients with a BCR-ABL1-like gene-expression signature. 17, 18 We found that deletions in these genes, including PAX5, VPREB1, TCF3, EBF1 and IKZF1, occurred in approximately 50% of an unselected cohort of DS ALL, which also included lowrisk patients. The incidence of PAX5 deletions reported in this study is rather low (12%) when compared with non-DS ALL patients (21-29%), 19, 29, 44 but similar to a group of non-DS ALL patients with genetically unclassified disease (B-other), as previously reported by Den Boer et al. 17 None of the DS ALL patients had deletions in EBF1, which is in correspondence to the low frequency reported in non-DS ALL. 17, 19, 29 The frequency of IKZF1 deletions in the unselected DCOG (35%) and UK cohorts (26%) is comparable to the 29% found in high-risk non-DS ALL patients 18 and to the 39% in a group of high-risk non-DS ALL patients with a 'BCR-ABL1-like' gene-expression signature. 17 Interestingly, 38% of the DCOG DS ALL have a gene-expression signature similar to those of BCR-ABL1-like non-DS ALL as identified in our previous study by a 110 probe-set based classifier. Within this DS-BCR-ABL1-like group, 40% has a deletion of IKZF1 similar to the frequency of IKZF1 deletions observed in non-DS BCR-ABL1-like cases. 17 Taken together, this suggests that a relatively large proportion of DS ALL patients have a genetic profile with characteristics of high-risk B-cell precursor ALL, and thus need to be treated accordingly, although this should be balanced against the increased risk of treatment-related mortality in DS children. Given that the option for intensification of chemotherapy in DS subjects are limited, it is a key to unravel the underlying biology of IKZF1 aberrant leukemias, in order to develop less toxic (targeted) therapy options for these patients. If confirmed in future studies or by other collaborative study groups, screening for evidence of high-risk genetic abnormalities, such as IKZF1, in DS ALL may lead to improved risk-group startification. The future DCOG ALL11 treatment protocol will already use IKZF1 deletions to assist in this and to tailor anthracycline exposure.
Recently, Mullighan et al. 12 reported that alterations of IKZF1 were associated with JAK2 R683 mutations in 87% of high-risk non-DS ALL patients. These patients had a 4-year CIR of 77%, from which the authors concluded that this defined a very poor risk subgroup. (a) Expression of probe 208303_s_at representing the CRLF2 gene after log transformation. Significant differences in median expression are shown between patients with CRLF2 wild type (n ¼ 8; 7.8) and patients with P2RY8-CRLF2 (n ¼ 15; 9.4), P ¼ 0.001, between P2RY8-CRLF2 and IGH@-CRLF2 translocation (n ¼ 4; 8.4, P ¼ 0.33) and between wild type and all patients with CRLF2 lesions, P ¼ 0.009. (b) Cumulative mRNA expression levels of CRLF2 relative to ribosomal protein S20 (%). Significant differences are observed between patients with wild-type CRLF2 (n ¼ 8; 0.001) and patients with P2RY8-CRLF2 (n ¼ 15; 6.5), Po0.001, between P2RY8-CRLF2 and IGH@-CRLF2 translocation (n ¼ 4; 0.001) and between wild type and all patients with CRLF2 lesions, P ¼ 0.02.
between non-DS and DS ALL patients, which is so far not very well understood.
Aberrations of CRLF2 are recently described genetic abnormalities in DS ALL, 8, 9, 13 occurring at a high frequency of B51% in this study. Some authors have used gene-expression profiling to screen for CRLF2 overexpression, however, this may occur independently from genomic aberrations in the CRLF2 gene. 13 Loudin et al. 20 identified with supervised clustering a geneexpression signature associated with high CRLF2 expression. After supervised clustering of our DCOG patients, genomic CRLF2-positive samples clustered separately from wild-type CRLF2 samples. However, only four genes with a false discovery Figure 4 . Kaplan-Meier estimates of DS ALL patients with and without IKZF1 aberrations. The 6-year EFS in DCOG DS ALL patients for IKZF1 is depicted in (a) and EFS for the UK data set is depicted in (d), the OS of DCOG DS ALL patients is shown in (b), the OS for the UK data set is depicted in (e), the CIR of DCOG DS ALL patients is shown in (c) and the CIR for the UK cohort is depicted in (f ). Patients with IKZF1 deletions have a significantly worse outcome in terms of OS, EFS and CIR compared with IKZF1 wild-type patients.
rate o10% were detected (data not shown), which implies that CRLF2 is not a strong signature. Furthermore, we found that DCOG DS ALL patients who carried the P2RY8-CRLF2 aberration had a significantly higher expression of CRLF2 compared with patients with a translocation of IGH@-CRLF2 or wild-type CRLF2, which is different from what is found in other studies, although this might be due to small numbers in our study. 8, 14 Moreover, we did not identify the CRLF2 expression level or genomic CRLF2 aberrations to be a significant risk factor for inferior treatment outcome, which is in agreement with the interim report of the Ponte di Legno on a large cohort of DS ALL patients 37 and several other DS and non-DS ALL studies, 7,9,16 but different from some other studies. 13, 15 In agreement with our findings, Harvey et al.
14 previously demonstrated in high-risk non-DS ALL patients that only IKZF1 deletions, but not CRLF2 aberrations, were independently associated with relapse. Furthermore, genomic aberrations of CRLF2 were strongly associated with JAK2 mutations. 7, 8, 14 Indeed, in our DS ALL cohort, all patients (n ¼ 5) with a JAK2 R683 mutation harbored P2RY8-CRLF2, although none of these patients experienced an event. Recently Hertzberg et al. 9 hypothesized that overexpression of CRLF2 is the first event in leukemogenesis of DS ALL, followed by mutations such as JAK2 and CRLF2. [6] [7] [8] 15 However, IKZF1 deletions, which disrupt normal lymphoid development, are not yet included in this model. Further research is needed to identify as to which of the aberrations is the primary event and how they cooperate in the pathogenesis of DS ALL.
Histone gene deletions have been recently reported by Loudin et al. 20 to be more common in DS ALL compared with non-DS ALL (22% vs 3.1%) patients, albeit without prognostic significance. In our DCOG cohort, only one (3%) DS ALL patient had a large deletion at the histone cluster at 6p22, whereas other patients showed only single probe deletions by array-CGH, which we consider to be below the threshold for true copy number changes. We did not search for point mutations, thus the involvement of the histone cluster may be underestimated in this study. In conclusion, we could not confirm a high frequency of histone deletions in DS ALL patients, but more sensitive techniques are needed.
In this study, minimal residual disease data were only available of a limited number of patients, and patients were treated on different protocols. Unfortunately, we therefore could not include this parameter in the multivariate analysis.
In conclusion, this study demonstrates that IKZF1 is a strong and independent predictor for poor clinical outcome in DS ALL, which was confirmed in an independent validation cohort of UK DS ALL patients. These data suggest that there are similarities between DS and non-DS ALL in relation to the underlying genetic background. A relatively large proportion of DS ALL patients has high-risk genetic characteristics and thus need to be treated accordingly, in balance with TRM. If confirmed in larger and prospective series, IKZF1 abnormalities may be integrated into risk stratification of DS ALL patients for treatment. 
